Features of the Retina Light Sensitivity in Patients with Chronic Cerebral Ischemia, Depending on the Stage of Discirculatory Encephalopathy with the Use of a Neuropeptide

Objective. Our study was to examine the degree of the light sensitivity impairment of the retina in patients with chronic cerebral ischemia, as well as to reveal the dynamics of these disorders on the background of the neuropeptide, depending on the stage of vascular encephalopathy.

Patients and methods. Comparative analysis of visual function was conducted in 70 persons (140 eyes). Patients were divided into 2 groups, each group is divided into two subgroups. To study the light sensitivity of the retina used automatic computer perimeter Hamphrey Field Analyzer HFA II — I Series (model 610, ZEISS, Germany).

Results. As a result of quantifying visual field defects in patients with chronic cerebral ischemia at 2 and 3 tbsp. vascular encephalopathy before treatment received preferential reduction of the light sensitivity of the retina in the temporal halves When comparing manual data with chronic cerebral ischemia patients 2 and 3 stadies vascular encephalopathy control group no significant differences before and after treatment have been identified. However, it is important to note that after 6 months treatment in the same group showed a slight increase in absolute numbers of cattle. In the control group using Cortexin observed reduction in the amount of absolute cattle.

Conclusions. The light sensitivity of the retina in patients with chronic cerebral ischemia decreases as the disease progresses, with a primary lesion of the temporal halves of the visual fields. The improvement in the computer perimetry during the treatment, especially in combination with cortexin can be attributed to the normalization of the retina cellular structures, improving the transfer of information and the partial restoration of the disturbed functions, which indicates the relative ischemia is reversible processes, which is effective in patients with stage 2 or 3 vascular encephalopathy. 

1. Maksudov G. A. Dyscirculatory encephalopathy. In the book.: Vascular diseases of the nervous system. Moscow: Medicine; 1975:501–512 (In Russ.).

2. Schmidt E.V. Classification of vascular lesions of the brain and spinal cord. Journal of Neurology and Psychiatry. C.C. Korsakov = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1985;85(9):192–203 (In Russ.).

3. Bergsneider M., Hovda D.A., Shalmon E., Kelly D.F., Vespa P.M., Martin N.A., Phelps M.E., Caron M.J., Kraus J.F., Besker D.P. Cerebral hyperglycolysis following severe human traumatic brain injury: a position emission tomography study. J Neurosurg. 1997;86:247–251. DOI: 10.3171/jns.1997.86.2.0241

4. Bramlett H.M., Dietrich W.D. Pathophysiology of cerebral ischemia and brain trauma: Similarities and differences. Journal of Cerebral Blood Flow and Metabolism. 2004;24:133–150. DOI: 10.1097/01.WCB.0000111614.19196.04

5. Dalkara T., Moskowitz M.A. The complex role of nitric oxide in the pathophysiology of focal cerebral ischemia. Brain-Pathol. 1994;4:49–57. DOI: 10.1111/j.17503639.1994.tb00810.x

6. Zoppo G.J., Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879–894. DOI: 10.1097/01.WCB.0000078322.96027.78

7. Cassidy T.P., Bruce D.W., Gray C.S. Visual field loss after stroke: confrontation and perimatry in the assessment of recovery. J Stroke Cerebrovasc Dis. 2001;10:113–117. DOI: 10.1053/jscd.2001.25457

8. Hanna K.L., Hepworth L.R., Rowe F.J. The treatment methods for post-stroke visual impairment: a systematic review. Brain Behav. 2017;7(5):e00682. DOI: 10.1002/brb3.682

9. Hanna K.L., Hepworth L.R., Rowe F.J. Screening methods for post-stroke visual impairment: a systematic review. Disabil Rehabil. 2017;39:2531–2543. DOI: 10.1080/09638288.2016.1231846

10. Hepworth L., Rowe F., Walker M. Post-stroke visual impairment: a systematic literature review of types and recovery of visual conditions. Ophthalmology Research: An International Journal. 2016;5:1–43. DOI: 10.9734/OR/2016/21767

11. Jones S.A., Shinton R.A. Improving outcome in stroke patients with visual propblems. Age Ageing. 2006;35:560–565. DOI: 10.1093/ageing/afl074

12. Johansen A., White S., Waraisch P. Screening for visual impairment in older people: validation of Cardiff Acuity Test. Arch Gerontol Geriatr. 2003;36:289–293. DOI: 10.1016/s0167-4943(02)00175-9

13. Macintosh C. Stroke re-visited: visual problems following stroke and their effect on rehabilitation. British Orthoptic Journal. 2003;60:10–14.

14. Rowe F.J. VIS writing Group. Vision In Stroke cohort: Profile overview of visual impairment Brain Behav. 2017;7:00771 DOI: 10.1002/brb3.771

15. Rowe F., Wright D., Brand D. Reading difficulty after stroke: ocular and non ocular causes. Int J Stroke. 2011;6:404–411. DOI: 10.1111/j.1747-4949.2011.00583.x

16. Rowe F., Brand D., Jackson C. Visual impairment following stroke: do stroke patients require vision assessment. Age Ageing. 2009;38:188–193. DOI: 10.1093/ageing/afn230

17. Rowe F.J. Who sees visual impairment following stroke? Strabismus. 2010;18:37–40. DOI: 10.3109/09273971003758396

18. Tsai S.Y., Cheng C.Y., Hsu W.M. Association between visual impairment and depression in the elderly. J Formos Med Assoc. 2003;102:86–90.

19. Wong T.Y., Klein R., Sharrett A.R. Cerebral white matter lesions, retinopathy and incident clinical stroke. JAMA. 2002;288:67–74. DOI: 10.1001/jama.288.1.67

20. Young A.R., Ali C., Duretete A., Vivien D. Neuroprotection and stroke: time for a compromise. J Neurochem. 2007;103:1302–1309. DOI: 10.1111/j.14714159.2007.04866.x

21. Adams H.P., del Zoppo G., Alberts M.J. Guidelines for the Early Management of Adults With Ischemic Stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary. Working Groups. Stroke. 2007;38:1655–1711. DOI: 10.1161/CIRCULATIONAHA.107.181486

22. Donnan G.A. A New Road Map for Neuroprotection. The 2007 Feinberg Lecture. Stroke. 2008;39:242. DOI: 10.1161/STROKEAHA.107.493296

23. Chacon M.R., Jensen M.B., Sattin J.A., Zivin J.A. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial. Curr Cardiol Rep. 2008;10(1):37–42. DOI: 10.1007/s11886-008-0008-2

24. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology, 04 Mar 2008, 55(3):363–389 DOI: 10.1016/j.neuropharm.2007.12.007

25. Ovbiagele B., Kidwell C.S., Starkman S., Saver J.L. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003;3(1):9–20. DOI: 10.1007/s11910-003-0031-z

26. Steiger H.J., Hanggi D. Ischaemic preconditioning of the brain, mechanisms and applications Acta Neurochir (Wien). 2007;149(1):1–10. DOI: 10.1007/s00701-0061057-1

27. Yenari M., Kitagawa K., Lyden P., Perez-Pinzon M. Metabolic Downregulation. A Key to Successful Neuroprotection? Stroke. 2008;39(10):2910–2917. DOI: 10.1161/STROKEAHA.108.514471

28. Maurice E. Langham. Ischemia and loss of autoregulation in ocular and cerebral diseases. Springer; 2009:121–125.